Gamida Cell Ltd (GMDA)

$0.32

-0.01

(-1.84%)

Market is closed - opens 8 PM, 11 Dec 2023

Performance

  • $0.32
    $0.33
    $0.32
    downward going graph

    1.56%

    Downside

    Day's Volatility :5.09%

    Upside

    3.59%

    downward going graph
  • $0.22
    $2.51
    $0.32
    downward going graph

    31.75%

    Downside

    52 Weeks Volatility :91.3%

    Upside

    87.25%

    downward going graph

Returns

PeriodGamida Cell Ltd
3 Months
-72.41%
6 Months
-83.84%
1 Year
-75.19%
3 Years
-96.77%

Highlights

Market Capitalization
43.8M
Book Value
$0.0
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.82
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
-2680.24%
Return On Assets TTM
-41.47%
Return On Equity TTM
-1103.79%
Revenue TTM
673.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-75.9M
Diluted Eps TTM
-0.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.71
EPS Estimate Next Year
-0.56
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Gamida Cell Ltd(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1150.0%

Current $0.32
Target $4.00

Technicals Summary

Sell

Neutral

Buy

Gamida Cell Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gamida Cell Ltd
Gamida Cell Ltd
-46.09%
-83.84%
-75.19%
-96.77%
-97.06%
Moderna, Inc.
Moderna, Inc.
14.4%
-34.97%
-51.36%
-48.82%
345.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.45%
11.42%
13.15%
75.11%
123.61%
Novo Nordisk A/s
Novo Nordisk A/s
-4.11%
21.75%
48.89%
177.94%
327.61%
Seagen, Inc.
Seagen, Inc.
2.71%
11.07%
66.1%
14.54%
259.34%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-7.59%
2.8%
11.45%
56.2%
102.13%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gamida Cell Ltd
Gamida Cell Ltd
NA
NA
NA
-0.71
-11.04
-0.41
0.0
0.0
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gamida Cell Ltd
Gamida Cell Ltd
Buy
$43.8M
-97.06%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
345.97%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
123.61%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
327.61%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
259.34%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
102.13%
26.38
35.94%

Institutional Holdings

  • ARK Investment Management LLC

    1.07%
  • Marshall Wace Asset Management Ltd

    0.01%
  • Lazard Asset Management LLC

    0.01%
  • Victory Capital Management Inc.

    0.01%

Corporate Announcements

  • Gamida Cell Ltd Earnings

    Gamida Cell Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.

Organization
Gamida Cell Ltd
Employees
143
CEO
Mr. Shai Lankry CPA, M.B.A.
Industry
Health Technology

FAQs